Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tanezumab: Phase III start

Pfizer disclosed on a conference call to discuss its 2Q13 earnings that it plans to resume Phase III trials next

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE